The Transition Experience of persons with Narcolepsy taking Oxybate in the Real-world (TENOR) study was conducted to provide real-world insight into the experience of people with narcolepsy switching from sodium oxybate (SXB) to low-sodium oxybate (LXB; 92% less sodium than SXB).TENOR is a patient-centric, prospective, observational, virtual-format ...
Charles J, Bae +7 more
openaire +4 more sources
Improvements in daytime sleepiness and disrupted nighttime sleep with once-nightly sodium oxybate in people with narcolepsy type 1 and type 2: a plain language summary [PDF]
What is this summary about? This is a plain language summary of a published article in the journal Sleep. Narcolepsy is a sleep condition that has 2 different subtypes: narcolepsy type 1 and narcolepsy type 2. These are called NT1 and NT2 for short.
Yves Dauvilliers +6 more
doaj +2 more sources
Treatments for enhancing sleep quality in fibromyalgia: a systematic review and meta-analysis. [PDF]
OBJECTIVES: Sleep disturbance is a key symptom of fibromyalgia and a risk factor for chronic widespread pain. This systematic review and meta-analysis aims to assess the effectiveness of pharmacological treatments and cognitive behavioural therapy (CBT ...
Pathak A +8 more
europepmc +6 more sources
Sialidosis type I: How to alleviate disabling myoclonic seizures?-A multicenter analysis of eight cases and review of the literature. [PDF]
Abstract Objective Sialidosis type I (ST‐1) is an autosomal‐recessive, very rare, progressive lysosomal storage disorder caused by pathogenic variants in NEU1. It is clinically characterized by progressive ataxia, myoclonic seizures (MS), bilateral tonic–clonic seizures (BTCS), and distinctive ophthalmological findings.
Gburek-Augustat J +15 more
europepmc +2 more sources
Narcolepsy is associated with disrupted nighttime sleep (DNS). Sodium oxybate (SXB; Xyrem®), administered twice nightly, is indicated for the treatment of cataplexy and excessive daytime sleepiness in patients 7 years or older with narcolepsy.
Russell Rosenberg +5 more
doaj +1 more source
Endogenous Levels, Detection Time, and Symptoms of Gamma-Hydroxybutyric Acid: Results From a Placebo-Controlled Clinical Trial. [PDF]
ABSTRACT Gamma‐hydroxybutyric acid (GHB), a potential agent in drug‐facilitated sexual assault, is difficult to detect due to rapid elimination, endogenous presence, and possible postsampling formation. We conducted a randomised, placebo‐controlled trial in 30 healthy volunteers, administering 50‐mg/kg sodium oxybate or placebo, to investigate symptoms,
Faldborg KB +3 more
europepmc +2 more sources
Sodium Oxybate: a Substitute for Alcohol?
Gamma-hydroxybutyrate (GHB) is a neurotransmitter found naturally in the human brain. Sodium oxybate (SO) is the sodium salt of GHB. In 2000 GHB was classified a Schedule I controlled substance, while SO became a Schedule III controlled substance for ...
A. Gual +3 more
doaj +1 more source
Sleep Dysfunction in Fibromyalgia and Therapeutic Approach Options [PDF]
Fibromyalgia, characterised by persistent pain, sleep disturbance, fatigue and cognitive dysfunction, is a central sensitivity syndrome that also involves abnormality in peripheral generators and in the hypothalamic pituitary adrenal axis.
Lawson, Kim
core +1 more source
In this review article, we present the treatment of narcolepsy since ancient times when patients experiencing the phenomenon of incubus (today understood as sleep paralysis with hypnagogic or hypnopompic hallucinations) were “cured” during the sessions ...
E. Sakalauskaitė-Juodeikienė +1 more
doaj +1 more source
Feasibility of following up gamma-hydroxybutyric acid concentrations in sodium oxybate (Xyrem®)-treated narcoleptic patients using dried blood spot sampling at home : an exploratory study [PDF]
Background: Gamma-hydroxybutyric acid (GHB), well known as a party drug, especially in Europe, is also legally used (sodium oxybate, Xyrem (R)) to treat a rare sleep disorder, narcolepsy with cataplexy.
Hertegonne, Katrien +3 more
core +1 more source

